BioCentury
ARTICLE | Financial News

Telix raises A$50M in Australian IPO

November 10, 2017 8:47 PM UTC

On Nov. 9, Telix Pharmaceuticals Ltd. (ASX:TLX) raised A$50 million ($38.3 million) through the sale of 77 million shares at A$0.65 in an IPO underwritten by Taylor Collison and Wilsons Corporate Finance. The price values the company at A$128.3 million ($98.3 million). Telix plans to begin trading on Nov. 15.

The company's lead program TLX-250 is based on radiolabeled girentuximab, a mAb that targets carbonic anhydrase IX (CAIX). The program includes diagnostic TLX-250i and therapeutic TLX-250t. Telix plans to begin an international Phase III trial of TLX-250i this year in patients with suspected or confirmed clear cell renal cell carcinoma (ccRCC), with a Phase II trial of TLX250t to treat ccRCC planned for mid-2018...